Mois : novembre 2019

Medicinal cannabis not proven in mental health, study finds, Kate Kelland, Reuters, 2019

Medicinal cannabis not proven in mental health, study finds Kate Kelland Reuters, Health News, October 28, 2019 LONDON (Reuters) - Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution, researchers said on Monday. In a review of scientific studies that analyzed the impact of medicinal cannabinoids on six mental health disorders, the researchers found “a lack of evidence for their effectiveness.” Their findings have important implications for countries such as the United States, Australia, Britain and Canada, where medical cannabis is being made available for patients with certain [...]

Lire la suite

IACM-Bulletin du 18 Novembre 2019

IACM-Bulletin du 18 Novembre 2019 IACM: L'Assemblée Générale élit Kirsten Mueller-Vahl à la présidence, modifie ses statuts et sa structure de cotisation Science/Homme: Le cannabis peut réduire la douleur chez les patients atteints d'endométriose Science/Homme: Selon une vaste étude épidémiologique, le cannabis pourrait réduire la dépression chez les patients présentant un trouble de stress post-traumatique Science/Homme: Le cannabis peut être bénéfique aux personnes âgées pour divers symptômes En bref Un coup d'œil sur le passé IACM: L'Assemblée Générale élit Kirsten Mueller-Vahl à la présidence, modifie ses statuts et sa structure de cotisation Lors [...]

Lire la suite

Safety and Efficacy of Medical Cannabis in Fibromyalgia, Iftach Sagy et al., 2019

Safety and Efficacy of Medical Cannabis in Fibromyalgia Iftach Sagy, Lihi Bar-Lev Schleider, Mahmoud Abu-Shakra and Victor Novack Journal of Clinical Medicine, 2019, 8, 807 doi : 10.3390/jcm8060807   Abstract : Background : Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. The aim of the study was to investigate the characteristics, safety, and eectiveness of medical cannabis therapy for fibromyalgia. Methods : A prospective observational study with six months follow-up period based on fibromyalgia patients who were willing to answer questionnaire in a specialized medical cannabis clinic between 2015 and 2017. Results : Among the [...]

Lire la suite

What Are the Benefits of CBD ?, New York Times, 16 octobre 2019

What Are the Benefits of CBD ? More than 60 percent of CBD users were taking it for anxiety, according to a survey of 5,000 people. Does it help? THE NEW YORK TIMES,   By Dawn MacKeen Published Oct. 16, 2019 https://www.nytimes.com/2019/10/16/style/self-care/cbd-oil-benefits.html Credit...Photo Illustration by The New York Times; Shutterstock The CBD industry is flourishing, conservatively projected to hit $16 billion in the United States by 2025. Already, the plant extract is being added to cheeseburgers, toothpicks and breath sprays. More than 60 percent of CBD users have taken it for anxiety, according to a survey of 5,000 people, conducted by the Brightfield Group, a cannabis market [...]

Lire la suite

FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease, 2019

FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease FDA is also working quickly to evaluate regulatory policies related to cannabis and cannabis-derived ingredients like CBD October 22, 2019 https://www.fda.gov/news-events/press-announcements/fda-ftc-warn-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-teething     Today, the U.S. Food and Drug Administration and the Federal Trade Commission posted a joint warning letter to Rooted Apothecary LLC, of Naples, Florida, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat teething pain and ear aches in infants, autism, attention-deficit/hyperactivity disorder (ADHD), as well as Parkinson’s and Alzheimer’s disease, [...]

Lire la suite

Research ethics aspects of experimentation with LSD on human subjects : a historical and ethical review, Bodnár Kristóf János & Kakuk Péter, 2018

Research ethics aspects of experimentation with LSD on human subjects : a historical and ethical review Bodnár Kristóf János, Kakuk Péter Medicine, Health Care and Philosophy © Springer Nature B.V. 2018 https://doi.org/10.1007/s11019-018-9871-9 Abstract In this paper our aim is to examine whether research conducted on human participants with LSD-25 (lysergic acid diethylamide) raises unique research ethical questions or demands particular concerns with regard to the design, conduct and follow-up of these studies, and should this be the case, explore and describe those issues. Our analysis is based on reviewing publications up to date which examine the clinical, research and other uses of LSD and those addressing [...]

Lire la suite

Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity, Rachael Ingram et al., 2018

Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity Rachael Ingram, Heather Kang, Stafford Lightman, David E. Jane, Zuner A. Bortolotto, Graham L. Collingridge, David Lodge, Arturas Volianskis Neuropharmacology, 2018, 142, 30e40 https://doi.org/10.1016/j.neuropharm.2018.06.008   Abstract Ketamine, a channel blocking NMDA receptor antagonist, is used off-label for its psychedelic effects, which may arise from a combination of several inter-related actions. Firstly, reductions of the contribution of NMDA receptors to afferent information from external and internal sensory inputs may distort sensations and their processing in higher brain centres. Secondly, reductions of NMDA receptormediated excitation of GABAergic interneurons can result in [...]

Lire la suite

Could cannabidiol be used as an alternative to antipsychotics ?, Marc Fakhoury, 2016

Could cannabidiol be used as an alternative to antipsychotics ? Marc Fakhoury Journal of Psychiatric Research · May 2016 Doi : 10.1016/j.jpsychires.2016.05.013   Abstract Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the [...]

Lire la suite

The Varieties of Psychedelic Epistemology, Chris Letheby, 2019

The Varieties of Psychedelic Epistemology Chris Letheby Published in N. Wyrd, D. Luke, A. Tollan, C. Adams, and D. King (eds.) : "Psychedelicacies: more food for thought from Breaking Convention", Strange Attractor Press, 2019.   INTRODUCTION Is it possible to gain knowledge1 by taking psychedelic2 drugs? One influential answer is ‘yes’: according to this conception, by inducing mystical states of consciousness, psychedelics afford direct knowledge of supernatural, transcendent dimensions of reality. This is an entheogenic conception of the drugs as agents that “generate the divine within”. A second influential answer is ‘no’: since materialism or physicalism3 is true, there are no transcendent realities, and psychedelics [...]

Lire la suite

Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy : a review, Mina Cheraghi Niroumand et al., 2015

Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: a review Mina Cheraghi Niroumand, Mohammad Hosein Farzaei, Gholamreza Amin Journal of Traditional Chinese Medicine, 2015, 35, (1), 104-109.   Abstract OBJECTIVE : To review the pharmacological activities of Peganum harmala L. (P. harmala, Nitrariaceae) in traditional Iranian medicine (TIM) and modern phytotherapy. METHODS : Opinions of TIM and modern phytotherapy about safety and acceptable dosage of this plant are discussed. Various medical properties of P. harmala were collected from important TIM references and added to scientific reports derived from modern medical databases like PubMed, Scirus, ScienceDirect and Scopus. RESULTS : The main medicinal [...]

Lire la suite